Stocks Slip as Pand...
Health Care: Drugs
Regeneron Pharmaceuticals Inc. (REGN: NASDAQ)
$250.31 -4.56 | -1.79%
05/24/13 - 04:00 PM ET
Portfolios with REGN
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Companies That Prove Sto...
- ContributorDrugs Facing FDA Approval i...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Stocks of Top-Performing...
- ContributorEarnings Short Squeeze Play...
- ContributorRelative Strength Trades fo...
- Contributor10 Stocks That Boosted Firs...
Latest REGN Headlines from TheStreet
- Today's Drugs Gainers Led By Regeneron Pharmaceuticals Inc. (REGN) 04.16.13 | 05:04 pm
- 4 Stocks Driving The Drugs Industry Higher 04.12.13 | 01:04 pm
- Regeneron Reaches New 52-Week High (REGN) 04.10.13 | 11:04 am
- Market Takes Aim at Historic Highs Once Again
04.10.13 | 09:04 am - Regeneron Pharmaceuticals Inc. (REGN) In The Drugs Spotlight Today 04.08.13 | 05:04 pm
- Regeneron Reaches New 52-Week High (REGN) 04.03.13 | 11:04 am
- Ampio's Eye Drug Trial Design Won't Pass FDA Muster 04.02.13 | 09:04 am
- 4 Stocks Raising The Health Care Sector Higher 04.01.13 | 01:04 pm
- Cramer's Top Stock Picks: PAYX REGN RHT FIVE PVH 03.29.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.28.13 | 08:03 pm
Press Releases for REGN
- BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals - PR Newswire 04.04.13 | 09:04 am
- Regeneron Named World's #1 Biopharmaceutical Employer In Science Magazine Annual Survey - PR Newswire 09.21.12 | 12:09 pm
- Sanofi And Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody - PR Newswire 07.20.12 | 01:07 am
- Sanofi And Regeneron Announce Publication Of Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody In The Lancet - PR Newswire 05.26.12 | 11:05 am
- Sanofi And Regeneron Announce Regulatory And Clinical Update For ZALTRAP® (aflibercept) - PR Newswire 04.05.12 | 01:04 am
- Sanofi And Regeneron Report Phase 2 Data For Potential First-in-Class Lipid-Lowering PCSK9 Antibody - PR Newswire 03.26.12 | 11:03 am
- Regeneron And Bayer Announce Approval Of EYLEA® (aflibercept) Injection For The Treatment Of Wet Age-Related Macular Degeneration In Australia - PR Newswire 03.08.12 | 04:03 am
- Two Year Results Of Phase 3 Studies With EYLEA⢠(aflibercept) Injection In Wet AMD Show Sustained Improvement In Visual Acuity - PR Newswire 12.05.11 | 02:12 am
- Regeneron And Bayer Initiate Phase 3 Clinical Program For The Treatment Of Wet Age-Related Macular Degeneration In China - PR Newswire 11.28.11 | 02:11 am
- Phase 3 Trial Of ZALTRAP⢠(aflibercept) In Advanced Prostate Cancer To Continue As Planned At Recommendation Of Independent Data Monitoring Committee - PR Newswire 07.07.11 | 07:07 am
Partner Headlines for REGN
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,264.63 up 48.14 points - NASDAQ 04.16.13 | 08:04 pm
- Indexes Finish With Solid Gains; After Hours Heats Up - Investor's Business Daily 04.16.13 | 05:04 pm
- Stocks Hold Near Highs; Regeneron Shoots To New Peak - Investor's Business Daily 04.16.13 | 03:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks End With Mild Losses; Nasdaq Rises 2.8% For Week - Investor's Business Daily 04.12.13 | 05:04 pm
- Regeneron's Flagship Drug Treats Blindness In Seniors - Investor's Business Daily 04.11.13 | 05:04 pm
- Buyers Put Money To Work; Dow, S&P 500 Touch Highs - Investor's Business Daily 04.09.13 | 04:04 pm
- Stocks Flat As Early Gains Fade; Regeneron Hits New High - Investor's Business Daily 04.09.13 | 10:04 am
- IBD Big Cap 20 Analysis: Some Stocks Show Resilience - Investor's Business Daily 04.08.13 | 06:04 pm
